▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials

N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the p...

Business Wire

N-Power Medicine to provide oncology clinics with needed research infrastructure to support Merck's oncology clinical trials.

REDWOOD CITY, Calif.: N-Power Medicine, a company reinventing the clinical trial process, is collaborating with Merck, known as MSD outside the United States and Canada, to enable a greater number of oncologists, and the patients they care for, to participate in clinical research. N-Power Medicine’s real-time registry and point-of-care platform combines technology, AI, and embedded research staff to deliver an integrated and efficient workflow for clinical research and routine patient care. Oncology practices in N-Power Medicine’s Clinical Research Network represent a new kind of clinical research site, with greater physician participation to increase access to clinical trials for eligible patients at the right time.

“We are proud to collaborate with Merck, a company that is leading innovation in the clinical development process and the acceleration of transformative medicines to people living with cancer,” said Mark Lee, M.D., Ph.D, N-Power Co-Founder and Chief Executive Officer. “This agreement underscores our commitment to partner with oncology clinics to bring the resources and reinvented framework that are needed to meaningfully expand access to more inclusive clinical research.”

N-Power Medicine and Merck are collaborating to implement multiple trials in the N-Power Medicine Network. The aim will be to broaden this new model for clinical development to other indications within oncology and to more cancer centers as the N-Power Medicine Network grows.

“We look forward to collaborating with N-Power Medicine to leverage their new approach to expanding clinical research to more people with cancer,” said Marjorie Green, M.D., Senior Vice President, Head of Oncology Clinical Development at Merck. “This provides the opportunity to foster critically-needed innovation in the cancer care ecosystem with the potential to benefit patients in urgent need of new therapies.”

Earlier this month, N-Power Medicine announced the initial close of a Series B funding round, raising its total funding to date to $72 Million. The Series B round was led by Merck Global Health Innovation Fund, with participation by a leading US-based healthcare focused investor. The funds will support the expansion of the company’s network of oncology clinics and biopharmaceutical company collaborations leveraging N-Power’s unique platform for integrating clinical research into everyday patient care.

About N-Power Medicine

N-Power Medicine is a clinical research and drug development platform company that aims to dramatically boost clinical trial participation to accelerate oncology drug development – and deliver on the promise of bringing life-saving innovation to cancer patients. Founded in 2021, the company addresses critical challenges for oncology sites by integrating technology and trained personnel into routine care to unlock the full potential of the data needed to bring new therapies to patients sooner. For more information on N-Power Medicine, visit www.npowermedicine.com and connect with us on LinkedIn.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Sparkle works on environmentally sustainable content distribution

The Italian company partners with MainStreaming for high-performance, energy-efficient video streaming

Fintech: Links tests the use of exponential technologies in the banking…

Links Management and Technology just concluded the testing phase of a research project focused on banking transformation

Axyon AI: Italian Artificial Intelligence for Finance applications

Axyon AI offers an AI platform specifically designed for asset management, with several interesting strengths for those approaching machine/deep learning…

Italian Artificial Intelligence tackles medical emergencies at sea

Mermaid-AI is a telehealth platform at sea based on a visor equipped with an AR, medical Artificial Intelligence algorithms, satellite communications…

Most read

Sparkle works on environmentally sustainable content distribution

The Italian company partners with MainStreaming for high-performance, energy-efficient video streaming

Biostate AI Launches Total RNA Sequencing and Free Data Analysis AI

Biostate AI, the scalable biodata foundry startup, emerges from stealth today with the launch of two service products: Total RNA sequencing and Copilot…

GlassHive Announces Integration with ConnectWise to Elevate the ConnectWise…

#businessautomation--GlassHive, a trailblazer in sales and marketing automation, has announced an integration with ConnectWise, a leading provider of…

ISG to Announce Second-Quarter Financial Results

$III #earnings--Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, said today it will release its…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!